Clinical trials: First Line Treatment
Primary Immune Thrombocytopenia (ITP)
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).
- Trial name
- NCT06992128
- Testing
- Romiplostim N01 combined with dexamethasone, Dexamethasone monotherapy
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
- Trial name
- CHAPLIN (NCT03911219)
- Testing
- eHealth system support for symptom management via CANKADO
- Where
- 92 sites in Germany
- Volunteers
- 154 people
- Sponsor
- iOMEDICO AG
Clostridium Difficile
Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
Clostridium difficile associated diarrhea (CDAD) is a significant cause of morbidity and mortality, caused by loss of healthy gut flora. Conventional treatment uses antibiotics to kill Clostridium difficile.
- Trial name
- NCT02801656
- Testing
- Fecal Microbiota Transplantation, Vancomycin
- Where
- Canada
- Sponsor
- Memorial University of Newfoundland
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Phase II trial to study the effectiveness of combining bortezomib with gemcitabine and carboplatin in treating patients who have advanced or recurrent non-small cell lung cancer that has not been previously treated with…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00075751
- Testing
- gemcitabine hydrochloride, carboplatin, bortezomib
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Cancer Institute (NCI)
Helicobacter Pylori Eradication
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Although,bismuth-containing quadruple therapy has been highly recommended as first-line treatment regimen for H.pylori infection,it also has its problems and limitations in China.The primary resistance rates of…
- Trial name
- NCT04558502
- Testing
- Minocycline hydrochloride capsule, Clarithromycin, Amoxicillin
- Volunteers
- 339 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
SCLC
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT05844150
- Testing
- PM8002, Platinum, Etoposide
- Where
- 17 sites in China
- Volunteers
- 50 people
- Sponsor
- Biotheus Inc.
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Metastatic Colorectal Cancer
Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in an homogeneous group of…
- Trial name
- PULSAR (NCT02173990)
- Testing
- Aflibercept-FOLFIRI
- Where
- 8 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Oscar Lambret
Urinary Bladder Neoplasm
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Autologous cellular immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer…
- Trial name
- NCT03389438
- Testing
- autologous Tcm cells immunotherapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Huanxing Cancer Hospital
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Pancreatic Cancer
Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer
This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in…
- Trial name
- ASAGPAC (NCT03636308)
- Testing
- nanoparticle albumin-bound paclitaxel, S1, Gemcitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Multiple Myeloma
VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates
Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope for the patients with multiple myeloma.
- Trial name
- NCT00320476
- Testing
- Velcade
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Korean Multiple Myeloma Working Party
Renal Cell Carcinoma (RCC)
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma…
- Trial name
- INSPIRE-RCC (NCT07852884)
- Testing
- First-line systemic regimens
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous…
- Trial name
- NCT07416474
- Testing
- RC148 plus Carboplatin and Paclitaxel, Tislelizumab plus Carboplatin and Paclitaxel
- Where
- 78 sites in China
- Volunteers
- 574 people
- Sponsor
- RemeGen Co., Ltd.
Steroid-refractory Acute Graft-versus-host Disease
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit…
- Trial name
- IDUNN (NCT04629833)
- Testing
- MC0518, BAT
- Where
- 42 sites in France, Germany and 3 more
- Volunteers
- 210 people
- Sponsor
- medac GmbH
RAS Wild Type mCRC
Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study
Analysis of freely circulating DNA in liquid biopsies using the BEAMing method
- Trial name
- PERSEIDA (NCT02792478)
- Where
- 24 sites in Spain
- Volunteers
- 238 people
- Sponsor
- Amgen
Helicobacter Infections
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter…
- Trial name
- NCT00816140
- Testing
- Cravit based triple therapy, Klaricid based triple therapy
- Where
- Taiwan
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).
- Trial name
- HP-BTC-001 (NCT05742750)
- Testing
- Camrelizumab and Apatinib Plus GP
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.